---
document_datetime: 2025-06-30 16:12:14
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/bropair-spiromax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: bropair-spiromax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.309783
conversion_datetime: 2025-12-26 11:27:54.557304
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - | 01/04/2025                          |                                             | PL                               |           |

BroPair Spiromax Procedural steps taken and scientific information after the authorisation* *Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) . Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| EMA/N/0000258678                      | Update of the package leaflet with revised details of local representatives and to delete United Kingdom (Northern Ireland) from the list of local representatives in line with QRD template v10.4. Additionally, the MAH removed the grey-shading for the manufacturer in section '6. Contents of the pack and other information' and took the opportunity to introduce a minor editorial amendment to the Lithuanian translation of the package leaflet. authorised   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000253346 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted 25/03/2025 N/A product no longer                                                                                                       |
| Variation type IA / EMA/VR/0000245601 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process 28/01/2025 Medicinal                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->